{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Indaptus Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"INDP"},"Address":{"label":"Address","value":"THREE COLUMBUS CIRCLE,15TH FLOOR, NEW YORK, New York, 10019, United States"},"Phone":{"label":"Phone","value":"646) 427-2727"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York."},"CompanyUrl":{"label":"Company Url","value":"https://www.indaptusrx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jeffrey A. Meckler","title":"Chief Executive Officer & Director"},{"name":"Michael James Newman","title":"Director & Chief Scientific Officer"},{"name":"Roger J. Waltzman","title":"Chief Medical Officer"},{"name":"Walt A. Linscott","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}